Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by Quantbot Technologies LP

Quantbot Technologies LP grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 36.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 25,422 shares of the company’s stock after acquiring an additional 6,841 shares during the quarter. Quantbot Technologies LP’s holdings in Omnicell were worth $1,132,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of OMCL. Pier Capital LLC bought a new stake in shares of Omnicell during the third quarter valued at about $5,859,000. Geode Capital Management LLC raised its position in shares of Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock worth $48,176,000 after buying an additional 2,877 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Omnicell during the 3rd quarter worth about $753,000. Shaker Investments LLC OH acquired a new stake in shares of Omnicell in the 4th quarter worth approximately $550,000. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Omnicell by 6.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company’s stock valued at $14,232,000 after acquiring an additional 20,031 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Trading Down 1.9 %

NASDAQ:OMCL opened at $34.47 on Wednesday. The stock has a fifty day simple moving average of $39.47 and a 200 day simple moving average of $42.75. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 127.67, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Sell-side analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

OMCL has been the topic of several recent analyst reports. JPMorgan Chase & Co. dropped their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Monday. Benchmark reaffirmed a “buy” rating and set a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Wells Fargo & Company dropped their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Bank of America cut their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Omnicell has an average rating of “Hold” and a consensus price target of $51.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.